Overexpression of p27 Inhibits HER-2 in Preclinical Tests
August 01, 2002
WASHINGTON-About 30% of breast cancer patients show overexpression of the HER-2/neu oncogene, and trastuzumab (Herceptin), a monoclonal antibody targeting HER-2, has been shown to block the gene’s receptor activity. But because the response rate to trastuzumab "is not ideal," there is "still a need for a better therapeutic agent" aimed at HER-2, said Mong-Hong Lee, PhD, assistant professor of molecular and cellular oncology, M.D. Anderson Cancer Center.